<DOC>
	<DOCNO>NCT02469259</DOCNO>
	<brief_summary>This study investigate effect oxytocin alcohol-related behavior , social ability , physiological startle response healthy individual patient posttraumatic stress disorder ( PTSD ) alcohol use disorder ( AUD ) use randomize , placebo-controlled , dose-tiered , between-subject study design . Specifically , investigator determine intranasal administration single dose pro-social neuropeptide oxytocin decrease alcohol-related approach bias craving , enhance social ability , decrease physiological hyperactivity . The investigator also determine optimal dose achieve effect explore psychosocial predictor responses oxytocin . The propose work potential yield novel pharmacological treatment AUD PTSD , lead cause disability US Military currently available treatment inadequate .</brief_summary>
	<brief_title>The Effects Oxytocin Startle Hyperreactivity Patients With AUD PTSD</brief_title>
	<detailed_description />
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Oxytocin</mesh_term>
	<criteria>1 . Ages 18 55 ( inclusive ) 2 . Current DSMV diagnosis PTSD 3 . Current ( past month ) DSMV diagnosis moderate severe Alcohol Use Disorder 1 . Psychotic disorder , bipolar disorder , dementia , psychiatric disorder judge unstable . 2 . Subjects know clinically significant unstable medical condition , include limit clinically significant renal disease and/or impair renal function define clinically significant elevation blood urea nitrogen ( BUN ) creatinine estimate creatinine clearance &lt; 60 mL/min , AST and/or ALT &gt; 5 time upper limit normal range and/or increase serum bilirubin &gt; 2 time upper limit normal . 3 . Current medication alcohol dependence ( disulfiram , naltrexone , acamprosate ) use past week . 4 . Needing acute medical detoxification alcohol base score 12 Clinical Institute Withdrawal Assessment Alcohol Scale ( CIWAAD ) ; 5 . Subjects legally mandate participate alcohol treatment program . 6 . Subjects suicide attempt past 6 month suicidal ideation 90 day prior enrollment . 7 . Subjects seizure disorder require anticonvulsant medication 8 . Positive urine pregnancy test , woman meet DSMV criterion premenstrual dysphoric disorder disease likely influence hormonal neuroendocrine status 9 . Sensitivity preservative ( particular E 216 , E 218 chlorobutanol hemihydrate ) 10 . Nasal obstruction , discharge , bleed 11 . Taking antipsychotic mood stabilizer , testosterone estrogen/progesterone supplement , 5HT1a agonists/antagonists , agent alter oxytocin level</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>oxytocin</keyword>
	<keyword>PTSD</keyword>
	<keyword>Alcohol Use Disorder</keyword>
	<keyword>social cognition</keyword>
	<keyword>crave</keyword>
	<keyword>fear-potentiated startle</keyword>
</DOC>